HIV, antiretroviral therapies, and the brain

被引：65

作者：

Liner II K.J. ^{[1
]}

Ro M.J. ^{[1
]}

Robertson K.R. ^{[1
]}

机构：

[1] Department of Neurology, University of North Carolina, 2127 Physician Office Building, Chapel Hill, NC 27599-7025

来源：

Current HIV/AIDS Reports | 2010年 / 7卷 / 2期

关键词：

Antiretroviral therapy; CNS; HIV-1; Impairment; Neurocognition;

D O I：

10.1007/s11904-010-0042-8

中图分类号：

学科分类号：

摘要：

While combination antiretroviral therapy (CART) has decreased the incidence of HIV-associated dementia, the severest form of HIV-associated neurocognitive disorders (HAND), mild neurocognitive disorder and asymptomatic neurocognitive impairment continue to persist, and there is evidence that neurocognitive deficits present even in acute HIV infection. Recent studies demonstrate that CART regimens with higher central nervous system (CNS) penetration effectiveness ranks may improve neurocognitive functioning. Considering these factors, earlier treatment initiation may be considered to protect the CNS. The functional impact of HAND on daily activities should be monitored. Areas that need further research are potential neurotoxicity of antiretrovirals, the eradication of potential latent reservoirs in the brain, when to start treatment to protect the CNS, and the neurological impact of HIVon the CNS in acute infection. © Springer Science+Business Media, LLC 2010.

引用

页码：85 / 91

页数：6

共 57 条

[1]

Antinori A., Arendt G., Becker J.T., Et al., Updated research nosology for HIV-associated neurocognitive disorders, Neurology, 69, pp. 1789-1799, (2007)

[2]

Robertson K.R., Smurzynski M., Parsons T.D., Et al., The prevalence and incidence of neurocognitive impairment in the HAART era, AIDS, 21, pp. 1915-1921, (2007)

[3]

Ellis R., Effects of CNS antiretroviral distribution on neurocognitive impairment in the AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) Study, 134th Annual Meeting of the American Neurolological Association. Baltimore, MD

[4]

October, pp. 11-14, (2009)

[5]

Sterne J.A., May M., Costagliola D., Et al., Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies, Lancet, 373, pp. 1352-1363, (2009)

[6]

Tozzi V., Balestra P., Salvatori M.F., Et al., Changes in cognition during antiretroviral therapy: Comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders, J Acquir Immune Defic Syndr, 52, pp. 56-63, (2009)

[7]

Marra C.M., Zhao Y., Clifford D.B., Et al., Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance, AIDS, 23, pp. 1359-1366, (2009)

[8]

Robertson K., Zhaohui S., Margolis D.M., Et al., Neurocognitive effects of treatment interruption in stable HIV + patients in an observational cohort: ACTG 5170, Neurology, (2010)

[9]

Letendre S., Revised CNS penetration-effectiveness ranks, 17th Conference on Retroviruses and Opportunistic Infections, (2010)

[10]

Patel K., Ming X., Williams P.L., Et al., Impact of HAART and CNS-penetrating antiretroviral regimens on HIV encephalopathy among perinatally infected children and adolescents, AIDS, 23, pp. 1893-1901, (2009)

← 1 2 3 4 5 6 →